

# **Lack of glucocorticoid-induced leucine zipper (GILZ) deregulates B-cell survival and leads in B-cell lymphocytosis in mice.**

M. Biagioli<sup>1</sup>, D. Sorcini<sup>2</sup>, S. Bruscoli<sup>2</sup>, O. Bereshchenko<sup>2</sup>, T. Frammartino<sup>2</sup>, M. Cimino<sup>2</sup>, and C. Riccardi<sup>2</sup>

<sup>1</sup>Dept. of Surgical Sciences and Biomedical, Section of Gastroenterology, University of Perugia, Italy

<sup>2</sup>Dept. of Medicine, Section of Pharmacology, University of Perugia, Italy

Glucocorticoids (GC) are widely used as immunosuppressive drugs and antitumor agents in some acute leukemias and multiple myeloma. Therapeutic doses of GC induce growth-suppressive and cytotoxic effects on various leukocytes including B cells. Molecular mechanisms of GC action include induction of GC target genes. Glucocorticoid-induced leucine zipper (GILZ), a member of Tsc22d family, is a rapidly, potently and invariably GC-induced gene. One of the TSC22d members were recently found mutated in diffuse large B cell lymphoma patients, suggesting that also TSC22d family members may play a role in lymphoma development. Our studies are needed to characterize the role of GILZ in normal and pathological hematopoiesis using of mouse models of knock-out mice (KO) for GILZ.

GILZ expression and function have been characterized in many hematopoietic lineages, including T cells, macrophages, and dendritic cells, but its role in B lymphocytes has not been addressed. To determine whether GILZ is expressed in B lymphocytes, BM cells from WT mice were analyzed by qPCR for the expression of GILZ at various stages of B-cell development. We have found that GILZ is expressed in all B-cell developmental stages at levels comparable with those of CD4<sup>+</sup>CD25<sup>-</sup> T cells. Young gilz KO mice showed normal body and lymphoid tissue weight and absolute counts of white blood cells, as well as B and T lymphocytes. However, the total number of BM cells was significantly higher in gilz KO mice compared with controls. Flow cytometry analysis of BM revealed an increase frequency and number of B220<sup>+</sup> cells in gilz KO mice compared with WT controls, whereas development of other hematologic lineages appeared normal. Flow cytometry analysis showed in KO mice a mild but significant increase in the frequency and absolute number starting from the PreB stage. Then we studied older mice to see if they develop leukemia/lymphoma overtime. We observed increased cellularity of BM, spleen and pLN in gilz KO mice compared with WT littermates. The increased lymphocyte number was the result of a specific accumulation of B220<sup>+</sup> B cells in mice lacking GILZ. Conversely, the number of CD4<sup>+</sup>, CD8<sup>+</sup>, and Mac-1<sup>+</sup> cells did not differ in respective organs of WT and gilz KO mice. To investigate whether the B-lymphocyte accumulation is a result of a decreased cell death, we tested the ability of WT and gilz KO B cells to survive in vitro. Purified CD19<sup>+</sup> cells lacking GILZ showed increase survival in vitro compared with WT B cells, as measured by cell counting after 48 hours in culture. Moreover we compared apoptosis in WT and GILZ-deficient B cells by AnnexinV staining. Results demonstrate that cells lacking GILZ have a decreased frequency of apoptotic cells in BM. Furthermore we evaluated cell proliferation and death in different B-cell subpopulations ex vivo by flow cytometry. Expression of ki67 was comparable in WT and gilz KO mice in all of the B-cell subsets, instead, B cells isolated from gilz KO mice revealed decreased caspase activation in all B-cell subsets starting from the PreB stage of B development. Then we monitored the expression levels of different Bcl-2 family members in cultured BM cells isolated from WT and gilz KO mice. The results gave the same directions. Furthermore here we found that GILZ interacts with the NF-kB p65 subunit in purified CD19<sup>+</sup> B cells as revealed by proximity ligation assay, suggesting that GILZ regulates NF-kB also in B cells. Consistently, we observed an increased nuclear translocation of the NF-kB p65 subunit in gilz-deficient B cells. Then we performed ChIP assay in CD19<sup>+</sup> B cells purified from WT or gilz KO animals. Results indicate that p65/NF-kB binds more to the Bcl-2 promoter in purified B cells lacking GILZ.

These results establish GILZ as an important regulator of B-cell survival and suggest that the deregulation of GILZ expression could be implicated in the pathogenesis of B-cell disorders.